{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14"],"submitter":["Montella L"],"pubmed_abstract":["Background
Hormone receptor-positive tumors are unlikely to exhibit a complete pathological tumor response. The association of CDK 4/6 inhibitor plus hormone therapy has changed this perspective.Case presentation
In this study, we retrospectively reviewed the charts of patients with a diagnosis of luminal A/B advanced/metastatic tumors treated with a CDK 4/6 inhibitor-based therapy. In this part of the study, we present clinical and ultrasound evaluation. Eight female patients were considered eligible for the study aims. Three complete and five partial responses were reported, including a clinical tumor response of 50% or more in five out of nine assessed lesions (55%). All patients showed a response on ultrasound. The mean lesion size measured by ultrasound was 27.1 ± 15.0"],"journal":["Frontiers in oncology"],"pagination":["1295772"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11058846"],"repository":["biostudies-literature"],"pubmed_title":["Case report: An ultrasound-based approach as an easy tool to evaluate hormone receptor-positive HER-2-negative breast cancer in advanced/metastatic settings: preliminary data of the Plus-ENDO study."],"pmcid":["PMC11058846"],"pubmed_authors":["Riccio V","Berretta M","Marino MA","Altucci L","Di Marino L","Montella L","Facchini G","Del Gaudio N"],"additional_accession":[]},"is_claimable":false,"name":"Case report: An ultrasound-based approach as an easy tool to evaluate hormone receptor-positive HER-2-negative breast cancer in advanced/metastatic settings: preliminary data of the Plus-ENDO study.","description":"Background
Hormone receptor-positive tumors are unlikely to exhibit a complete pathological tumor response. The association of CDK 4/6 inhibitor plus hormone therapy has changed this perspective.Case presentation
In this study, we retrospectively reviewed the charts of patients with a diagnosis of luminal A/B advanced/metastatic tumors treated with a CDK 4/6 inhibitor-based therapy. In this part of the study, we present clinical and ultrasound evaluation. Eight female patients were considered eligible for the study aims. Three complete and five partial responses were reported, including a clinical tumor response of 50% or more in five out of nine assessed lesions (55%). All patients showed a response on ultrasound. The mean lesion size measured by ultrasound was 27.1 ± 15.0","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024","modification":"2026-06-02T22:47:22.787Z","creation":"2026-04-21T03:13:31.821Z"},"accession":"S-EPMC11058846","cross_references":{"pubmed":["38690171"],"doi":["10.3389/fonc.2024.1295772"]}}